Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer

Michael Overman, Milind Javle, Richard E. Davis, Pankaj Vats, Chandan Kumar-Sinha, Lianchun Xiao, Niharika B. Mettu, Edwin R. Parra, Al B. Benson, Charles D. Lopez, Veerendra Munugalavadla, Priti Patel, Lin Tao, Sattva Neelapu, Anirban Maitra

Research output: Contribution to journal › Article › peer-review

68 Scopus citations

Fingerprint

Dive into the research topics of 'Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences